Tag: Lung Cancer: Non-Small Cell

SUMMARY: The American Cancer Society estimates that for 2026, about 229,410 new cases of lung cancer will be diagnosed and 124,990 patients will die of the disease. Lung cancer is the leading cause of cancer-related mortality in the United States. Non-Small Cell Lung Cancer (NSCLC) accounts for approximately 85% of all lung cancers. Of the three main subtypes of NSCLC, 30% are Squamous Cell Carcinomas (SCC), 40% are Adenocarcinomas and 10% are Large Cell Carcinomas. Approximately 10-15% of Caucasian patients and 35-50% of Asian patients with Adenocarcinomas, harbor activating EGFR (Epidermal Growth Factor Receptor) mutations and 90% of these mutations are either Exon 19 deletions or L858R substitution mutation in Exon 21.

The management of advanced EGFR-mutated NSCLC has evolved substantially with the introduction of third-generation EGFR tyrosine kinase inhibitors (TKIs), particularly Osimertinib (TAGRISSO®), which has become the preferred first-line therapy because of its superior efficacy, CNS activity, and favorable tolerability. Nevertheless, a substantial proportion of patients experience early molecular persistence despite treatment initiation, suggesting the presence of residual resistant tumor clones that ultimately drive disease progression.

The recently reported Phase II FLAME study introduces an innovative precision oncology strategy by demonstrating that early circulating tumor DNA (ctDNA)-guided treatment escalation can identify these high-risk patients and significantly improve clinical outcomes. Unlike conventional management that relies primarily on baseline molecular profiling followed by radiographic assessment every few months, FLAME leveraged serial plasma ctDNA monitoring as a dynamic biomarker to evaluate treatment response within just three weeks of initiating Osimertinib. Persistent detection of EGFR mutations in plasma at this early time point has previously been associated with inferior Progression-Free Survival (PFS) and Overall Survival (OS), suggesting incomplete molecular response despite ongoing targeted therapy.

The FLAME investigators hypothesized that these patients might benefit from immediate treatment intensification rather than waiting for radiographic progression.

Study Design

FLAME was a multicenter, randomized, open-label Phase II study enrolling patients with previously untreated locally advanced or metastatic NSCLC harboring common sensitizing EGFR exon 19 deletion or L858R mutations. All patients initially received first-line Osimertinib monotherapy. Plasma samples obtained after three weeks of treatment were analyzed using the highly sensitive Super ARMS-PCR assay to detect persistent EGFR-mutant ctDNA. Among 448 screened patients, 134 (approximately 30%) continued to demonstrate detectable plasma EGFR mutations after three weeks, identifying a molecularly high-risk subgroup. Eighty eligible patients (N=80) were randomized in a 1:1 ratio either to continue Osimertinib alone or to receive intensified treatment with Osimertinib combined with Carboplatin and Pemetrexed.  Both treatment groups were well balanced. Median age was 59 yrs, 58% were female and 35% had CNS metastases. Randomization was stratified according to baseline CNS metastases and EGFR mutation subtype (exon 19 deletion versus L858R). The Primary endpoint was investigator-assessed PFS according to RECIST version 1.1, while Secondary endpoints included Objective Response Rate (ORR), Duration of Response (DoR), Disease Control Rate, 18-month OS rate, safety, mechanisms of resistance, and exploratory analyses evaluating dynamic multi-omics biomarkers and patient-reported Quality of Life.

Significant Improvement in Progression-Free Survival

With a median follow-up corresponding to 67.5% PFS maturity, the addition of Platinum-Pemetrexed chemotherapy to Osimertinib resulted in a statistically significant and clinically meaningful improvement in PFS. Median PFS increased from 12.7 months with continued Osimertinib alone to 23.1 months with combination therapy, representing an absolute improvement of more than 10 months. The risk of disease progression or death was reduced by 47% (HR 0.53; 95% CI 0.31–0.92; P=0.024).

Tumor response also favored the intensified treatment strategy. The investigator-assessed ORR increased from 35% with Osimertinib monotherapy to 50% with combination therapy, while median Duration of Response improved from 10.5 months to 15.6 months. Although OS data remain immature, the observed PFS benefit suggests that intervening before overt clinical resistance develops may substantially delay disease progression in patients identified as molecular nonresponders.

ctDNA as an Early Response Biomarker

Perhaps the most important contribution of FLAME extends beyond the chemotherapy comparison itself. The study provides prospective validation of ctDNA-guided adaptive therapy, demonstrating that serial molecular monitoring can identify patients requiring treatment modification weeks before conventional imaging would reveal progressive disease.

Approximately one-third of screened patients exhibited persistent plasma EGFR mutations after three weeks of Osimertinib, confirming that early molecular clearance is heterogeneous despite identical initial therapy. These findings support the concept that molecular response kinetics reflect treatment sensitivity and residual tumor burden more accurately than baseline genomic profiling alone.

This adaptive treatment paradigm differs fundamentally from traditional precision oncology, which generally bases therapeutic decisions on static genomic testing performed before treatment initiation. Instead, FLAME illustrates how longitudinal ctDNA assessment may enable real-time therapeutic adjustment according to evolving tumor biology.

Relationship to FLAURA2

The FLAME findings complement the landmark Phase III FLAURA2 trial while addressing a distinct clinical question. FLAURA2 demonstrated that administering Osimertinib together with Platinum-Pemetrexed chemotherapy upfront for all eligible patients significantly prolonged PFS and subsequently improved OS, compared with Osimertinib alone, establishing the combination as an important first-line option for selected patients.

In contrast, FLAME evaluated a biomarker-directed strategy in which chemotherapy was reserved only for patients who demonstrated persistent ctDNA positivity after three weeks of Osimertinib. This selective escalation approach may allow clinicians to spare patients who achieve rapid molecular clearance from chemotherapy-related toxicities while intensifying treatment only in those at highest risk for early progression.

If validated in larger studies, this strategy could represent a more individualized alternative to universal upfront combination therapy.

Safety Profile

As expected, the improved efficacy of combination treatment was accompanied by increased toxicity. Grade 3 or higher treatment-related adverse events occurred in 65% of patients receiving Osimertinib plus Carboplatin-Pemetrexed compared with 10% of patients receiving Osimertinib alone. Importantly, the adverse-event profile remained consistent with the known toxicities of platinum-based chemotherapy and Osimertinib, and investigators reported no unexpected safety signals. Toxicities were considered manageable with standard supportive care and dose modifications.

Clinical Implications

The FLAME study represents one of the strongest prospective demonstrations that serial ctDNA monitoring can directly inform treatment decisions in metastatic EGFR-mutated NSCLC. Rather than serving solely as a prognostic biomarker, ctDNA becomes an actionable tool capable of identifying patients who benefit from early therapeutic intensification before radiographic progression develops.

This strategy has several potential clinical advantages.

1) Early molecular assessment may allow oncologists to intervene during a window when resistant clones remain limited in number, potentially delaying the emergence of clinically significant resistance.
2) It also introduces a risk-adapted treatment model in which chemotherapy is selectively administered to patients with demonstrated molecular persistence rather than universally to all patients at diagnosis.

The study further supports growing interest in integrating serial liquid biopsy into routine management of oncogene-driven lung cancers, not only for resistance mutation detection at progression but also for monitoring early treatment effectiveness and guiding adaptive therapeutic strategies.

Future Directions

Although highly encouraging, FLAME remains a Phase II study with a relatively modest sample size. Longer follow-up will be needed to determine whether the substantial improvement in PFS translates into an OS advantage. Planned analyses examining resistance mechanisms, dynamic multi-omics biomarkers, and Quality-of-Life outcomes may further refine patient selection and clarify which molecular features predict the greatest benefit from treatment escalation.

Larger Phase III studies will be essential before ctDNA-guided escalation becomes a routine component of first-line EGFR-mutated NSCLC management. Nevertheless, FLAME establishes an important proof of concept that precision oncology can evolve beyond baseline genomic testing toward continuous molecular monitoring that dynamically informs treatment decisions throughout the course of therapy.

Clinical Perspective  

FLAME introduces a paradigm shift in the management of EGFR-mutated advanced NSCLC by demonstrating that early molecular response, rather than baseline genotype alone, can guide individualized therapy. Patients with persistent plasma ctDNA after three weeks of Osimertinib experienced a marked improvement in PFS when chemotherapy was introduced early, providing prospective evidence that adaptive, biomarker-driven treatment intensification can improve outcomes in a biologically defined high-risk population. As liquid biopsy technologies become increasingly integrated into routine oncology practice, ctDNA-guided treatment adaptation may represent the next major step toward truly personalized therapy for patients with oncogene-driven lung cancer.

Osimertinib with/without chemotherapy in patients with persistent ctDNA EGFR mutant (EGFRm) NSCLC at 3 weeks after 1L osimertinib: A randomized phase II study (FLAME study). Wang Z, Zhong J, Duan J, et al. J Clin Oncol 44, LBA101(2026)

SUMMARY: The American Cancer Society estimates that for 2026, about 229,410 new cases of lung cancer will be diagnosed and 124,990 patients will die of the disease. Lung cancer is the leading cause of cancer-related mortality in the United States. Non-Small Cell Lung Cancer (NSCLC) accounts for approximately 85% of all lung cancers and adenocarcinoma is now the most frequent histologic subtype of lung cancer. The evolution of precision oncology in NSCLC continues to move beyond the metastatic setting, with targeted therapies increasingly demonstrating meaningful benefits in earlier stages of disease.

The Rationale for Targeting RET in Early Disease

RET kinase is a transmembrane Receptor Tyrosine Kinase and plays an important role during the development and maintenance of a variety of tissues, including neural and genitourinary tissues. RET signaling activates downstream pathways such as JAK/STAT3 and RAS/RAF/MEK/ERK and leads to cellular proliferation, survival, invasion, and metastasis. Oncogenic alterations to the RET proto-oncogene result in uncontrolled cell growth and enhanced tumor invasiveness. RET alterations include RET rearrangements, leading to RET fusions, and activating point mutations occurring across multiple tumor types. RET fusions have been identified in approximately 2% of NSCLCs, 10-20% of non-medullary thyroid cancers. Activating RET point mutations account for approximately 60% of sporadic Medullary Thyroid Cancers (MTC) and more than 90% of inherited MTCs. Other cancers with documented RET alterations include colorectal, pancreas, breast, and several hematologic malignancies.

Selpercatinib (RETEVMO®) is a highly selective and potent, CNS–penetrant RET inhibitor, designed to inhibit native RET signaling, as well as anticipated acquired resistance mechanisms. Selpercatinib selectively targets wild-type RET as well as various RET mutants and RET-containing fusion products. Additionally, Selpercatinib inhibits Vascular Endothelial Growth Factor Receptor 1 (VEGFR1), VEGFR3, Fibroblast Growth Factor Receptor 1 (FGFR1), FGFR2, and FGFR3. This results in inhibition of cell growth of tumors that exhibit increased RET activity. This agent has already demonstrated substantial clinical benefit in advanced and metastatic RET fusion–positive NSCLC, leading to its adoption as a standard targeted treatment in that setting.

While targeted therapies directed against EGFR mutations and ALK rearrangements have transformed postoperative management of early-stage NSCLC, patients with RET fusion–positive diseases have not previously had a comparable adjuvant treatment option. Consequently, recurrence following definitive therapy has remained a major concern.

LIBRETTO-432 was designed to determine whether earlier intervention with RET-directed therapy could alter the natural history of the disease and improve long-term outcomes.

Trial Design and Patient Population

LIBRETTO-432 was a global, randomized, double-blind, placebo-controlled Phase 3 study that enrolled 151 patients across 22 countries with Stage IB–IIIA RET fusion–positive NSCLC who had completed definitive locoregional treatment. Participants were randomized in a 1:1 ratio to receive either Sselpercatinib 160 mg twice daily (N=75) or Placebo (N=76) for up to three years. Importantly, the study allowed crossover from placebo to Selpercatinib in the event of disease recurrence, providing patients access to targeted therapy while also enabling assessment of adjuvant treatment benefit. Baseline characteristics were well balanced between treatment arms, ensuring robust comparisons between groups. The Primary endpoint was investigator-assessed Event Free Survival (EFS) in patients with Stage II–IIIA disease. Secondary endpoints included EFS in the overall study population, Blinded Independent Central Review (BICR)-assessed EFS, Overall Survival, and Safety. Median follow-up was 24 months for Selpercatinib and 27 months for Placebo.

Striking Reduction in Recurrence Risk

At the prespecified efficacy analysis, Selpercatinib demonstrated a profound and statistically significant improvement in EFS among patients with Stage II–IIIA disease. The risk of recurrence, progression, or death was reduced by approximately 83% compared with placebo, with a Hazard Ratio of 0.172 (P=0.0003). Median EFS was not reached in the Selpercatinib arm, whereas patients receiving placebo experienced a median EFS of 31.8 months. Only four EFS events occurred among patients receiving Selpercatinib compared with 19 events in the placebo group, underscoring the magnitude of benefit observed.

The separation of the survival curves was reflected in the 24-month EFS rates, which reached 91.5% with Selpercatinib compared with 61.1% with placebo. Independent Central Review confirmed these findings, demonstrating a consistent treatment effect and strengthening confidence in the robustness of the results.

Benefit Extends Across the Overall Study Population

The efficacy advantage observed in the primary analysis population was mirrored in the broader cohort of patients with Stage IB–IIIA disease. In the overall study population, Selpercatinib reduced the risk of an EFS event by approximately 84%, yielding a hazard ratio of 0.165 (P=0.0002). At two years, EFS rates were 93.8% in the Selpercatinib arm compared with 69.6% in the placebo group. The consistency of benefit across both primary and secondary analyses highlights the potential of RET inhibition to become an integral component of postoperative management for RET fusion–positive NSCLC.

Early Survival Signals and Crossover Experience

Although Overall Survival data remain immature, early observations are encouraging.

After a median follow-up of approximately 25 months in the Selpercatinib group, no deaths had been reported. In contrast, three deaths occurred in the placebo arm, all attributed to disease progression.

The crossover design provided valuable insight into treatment sequencing. Sixteen patients initially assigned to placebo crossed over to Selpercatinib after recurrence, with the majority remaining on treatment at the time of analysis. While crossover may ultimately dilute differences in Overall Survival between treatment groups, the substantial EFS benefit observed emphasizes the value of introducing targeted therapy before recurrence occurs.

Manageable Safety Profile Consistent With Prior Experience

The safety findings from LIBRETTO-432 were generally consistent with the established profile of Selpercatinib in advanced RET fusion–positive NSCLC. The most commonly reported grade 3 or higher toxicities included elevations in liver enzymes, specifically ALT and AST, as well as hypertension. Most events were manageable through dose modifications and routine clinical monitoring. Treatment discontinuation due to adverse events occurred in 17.3% of patients receiving Selpercatinib, compared with 1.3% of those receiving placebo. Importantly, no deaths occurred during assigned study treatment, and all reported deaths were confined to the placebo arm as a consequence of disease progression.

These findings suggest that while long-term therapy requires careful toxicity management, the benefit-risk profile remains favorable in light of the substantial reduction in recurrence risk.

Reinforcing the Importance of Comprehensive Biomarker Testing

One of the most important implications of LIBRETTO-432 extends beyond the efficacy of Selpercatinib itself. The study reinforces the necessity of comprehensive genomic profiling at the time of NSCLC diagnosis, regardless of disease stage.

Historically, molecular testing has often been prioritized in advanced disease where treatment decisions depend heavily on biomarker status. However, the emergence of effective adjuvant targeted therapies across multiple genomic subsets, including EGFR, ALK, and now potentially RET, demonstrates that molecular characterization has become equally critical in early-stage disease. Failure to identify actionable alterations at diagnosis may result in missed opportunities to offer therapies capable of substantially reducing recurrence risk and improving long-term outcomes.

Looking Ahead

The success of LIBRETTO-432 reflects a broader transformation in thoracic oncology. Increasingly, therapies initially developed for metastatic disease are being evaluated in earlier-stage settings where the potential impact on cure is greatest. LIBRETTO-432 is the first randomized Phase 3 study to evaluate a RET inhibitor in the adjuvant setting for early-stage RET fusion–positive NSCLC, and its results represent a major advance for this patient population.

With an approximately 83% reduction in the risk of recurrence, progression, or death, Selpercatinib delivered a clinically meaningful and statistically significant improvement in Event-Free Survival while maintaining a manageable safety profile. These findings position adjuvant Selpercatinib as a potential new standard of care for patients with resected RET fusion–positive NSCLC.

Event-free survival with adjuvant selpercatinib in stage IB-IIIA RET fusion-positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial. Goldman JW, Yang X, Hochmair M, et al. J Clin Oncol 44, 2026 (suppl 17; abstr LBA3)

SUMMARY: The American Cancer Society estimates that for 2026, about 229,410 new cases of lung cancer will be diagnosed and 124,990 patients will die of the disease. Lung cancer is the leading cause of cancer-related mortality in the United States. Non-Small Cell Lung Cancer (NSCLC) accounts for approximately 85% of all lung cancers and adenocarcinoma is now the most frequent histologic subtype of lung cancer.

Approximately 10-15% of Caucasian patients and 35-50% of Asian patients with adenocarcinomas, harbor activating EGFR (Epidermal Growth Factor Receptor) mutations, and 90% of these mutations are either exon 19 deletions or L858R substitution mutation in exon 21. EGFR exon 20 insertion mutations are the third most common after L858R and exon 19 deletions and occur in about 2-3% of all patients with NSCLC and  up to 12% of EGFR-mutated NSCLC . These mutations are also enriched in women, non-smokers, Asian populations, and those with adenocarcinoma.These highly heterogeneous group of mutations are typically associated with limited sensitivity to conventional EGFR Tyrosine Kinase Inhibitors (TKIs) due to an altered conformation of the kinase active site. Next-Generation sequencing provides an alternative to Polymerase Chain Reaction (PCR)-based tests, which fail to identify 50% or more of exon 20 insertion mutations. Patients with EGFR exon 20 insertion mutations have a 5-year Overall Survival (OS) of 8% in the frontline setting, compared to an OS of 19% for patients with EGFR exon 19 deletions or L858R mutations. Further, the use of immunotherapy is detrimental in this patient population and there is therefore a clinically unmet need for this patient group.

The treatment landscape for patients with advanced NSCLC harboring EGFR exon 20 insertion (ex20ins) mutations continues to evolve, with emerging targeted therapies offering new opportunities to improve outcomes in this historically challenging patient population.

Sunvozertinib (ZEGFROVY®), a novel oral, selective, and irreversible EGFR TKI specifically designed to target EGFR exon 20 insertion mutations, has already received regulatory approval in the United States and China for previously treated patients whose disease progressed following platinum-based chemotherapy. Building on encouraging efficacy observed in the pivotal WU-KONG1B and WU-KONG6 studies, the global Phase 3 WU-KONG28 trial evaluated whether Sunvozertinib could improve outcomes when used as first-line therapy.

WU-KONG28: Evaluating a Chemotherapy-Free First-Line Approach

WU-KONG28 (NCT05668988) is a multinational, randomized Phase 3 study, comparing Sunvozertinib with standard platinum-based chemotherapy, in treatment-naïve patients with advanced nonsquamous NSCLC harboring EGFR exon 20 insertion mutations.

A total of 324 patients were randomized 1:1 to receive either oral Sunvozertinib 300 mg once daily (N=163) until disease progression, or Carboplatin plus Pemetrexed chemotherapy (N=161) administered every three weeks for up to six cycles, followed by Pemetrexed maintenance. Patients assigned to chemotherapy were permitted to cross over to Sunvozertinib following centrally confirmed disease progression. The Primary endpoint was Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR), while key Secondary endpoints included Overall Survival (OS), Objective Response Rate (ORR), Duration of Response (DoR), and Safety.

Significant Improvement in Progression-Free Survival

At the January 16, 2026 data cutoff, Sunvozertinib demonstrated a statistically significant and clinically meaningful improvement in PFS compared with chemotherapy. Median PFS reached 10.3 months with Sunvozertinib versus 7.5 months with chemotherapy, corresponding to a 35% reduction in the risk of disease progression or death (HR 0.65; 95% CI, 0.50–0.85; P=0.0008).

Notably, separation of the PFS curves occurred early, suggesting rapid disease control with targeted therapy. At 12 months, 46.1% of patients receiving Sunvozertinib remained progression-free compared with 26.7% of patients treated with chemotherapy. The PFS advantage was generally consistent across analyzed patient subgroups.

Higher Response Rates and More Durable Tumor Control

Beyond prolonging PFS, Sunvozertinib achieved substantially deeper and more durable responses. The confirmed ORR was 58.9% with Sunvozertinib compared with 31.1% with chemotherapy. Patients receiving Sunvozertinib also experienced greater tumor shrinkage, with a median best percentage reduction in target lesions of 42.1% versus 24.7% in the chemotherapy arm.

Response durability further favored the targeted agent, with a median DoR of 11.2 months compared with 7.1 months for chemotherapy. These findings reinforce earlier clinical observations that Sunvozertinib provides robust antitumor activity across a broad spectrum of EGFR exon 20 insertion subtypes.

Overall Survival Data Still Maturing

Overall Survival analyses remain immature, with data maturity at 38.9% at the time of analysis. Interpretation of future OS results may be influenced by the study’s crossover design, as more than 90% of chemotherapy-treated patients with confirmed disease progression subsequently crossed over to receive Sunvozertinib.

While longer follow-up is needed to determine whether the PFS and response advantages translate into an Overall Survival benefit, the current efficacy results strongly support the clinical activity of Sunvozertinib in the frontline setting.

Manageable Safety Profile Supports Long-Term Use

The safety profile observed in WU-KONG28 was consistent with previous studies of Sunvozertinib. Grade 3 or higher adverse events occurred in 75.5% of patients receiving Sunvozertinib compared with 56.7% of patients receiving chemotherapy. The most frequently reported high-grade toxicities included elevated serum creatine kinase levels, diarrhea, and anemia.

Importantly, treatment discontinuation due to drug-related adverse events occurred in only 7.4% of patients, and no treatment-related deaths were reported. Severe rash was uncommon, and although grade 3 or higher diarrhea occurred in approximately 13.5% of patients, these events were generally manageable through proactive monitoring, supportive care, and dose modifications. The majority of patients were able to maintain treatment, reflected by a median relative dose intensity of 95%.

Implications for Clinical Practice

Historically, treatment options for EGFR exon 20 insertion-positive NSCLC have been limited, with platinum-based chemotherapy delivering modest response rates and relatively short progression-free survival. While the addition of targeted antibodies such as Amivantamab has improved outcomes, these approaches still rely on intravenous chemotherapy-based regimens.

The WU-KONG28 results position Sunvozertinib as a compelling chemotherapy-free alternative. As an oral targeted therapy, Sunvozertinib offers the potential for improved convenience and quality of life while delivering superior efficacy compared with standard platinum-doublet chemotherapy.

Looking Ahead

The WU-KONG28 trial represents a significant milestone in the treatment of EGFR exon 20 insertion-positive NSCLC. Sunvozertinib demonstrated superior Progression-Free Survival, higher response rates, greater tumor shrinkage, and longer response durability compared with standard chemotherapy, while maintaining a manageable and predictable safety profile.

As Overall Survival data continue to mature, these findings provide strong evidence supporting Sunvozertinib as a potential new first-line standard of care for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations, further advancing the shift toward personalized, targeted treatment strategies in lung cancer.

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations. Zhou C, Greillier L, Liu G, et al. or the WU-KONG28 Investigators. Published May 29, 2026. DOI: 10.1056/NEJMoa2604461